Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV) (PAIR HPV)

September 2, 2025 updated by: Institut Curie

Innovation for Standard Identification for Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cance: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV : Human PapillomaVirus)

Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Besançon, France, 25000
        • CHU Besançon
      • Caen, France, 14076
        • Centre François Baclesse
      • Clermont-Ferrand, France, 63000
        • Centre Jean Perrin
      • Paris, France, 75005
        • Institut CURIE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patient with cervical cancer, at any stage, before any anti-tumoral treatment.
  2. Age ≥ 18 years.
  3. Patient information and signature of the informed consent or her/his legal representative.
  4. Patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved.

Exclusion Criteria:

  1. Person deprived of liberty or under supervision.
  2. Inability to attend scheduled follow-up visits for any psychological, sociological or geographical reasons.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Tumor biopsies and blood sampling
Procedure: Tumor biopsy
Tumor biopsy before treatment
Procedure: Blood sampling
Blood sample before, during and after treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.
Time Frame: Until 2 years after treatment

Detection rate of circulating tumoral DNA with confidence interval of 95% of this rate.

Description of the variability of this rate according to the initial stage of the disease, treatment and disease progression.
Until 2 years after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validation of NGS methodology for the molecular characterization of genetic alterations related to the integration of viral DNA sequences.
Time Frame: Until 2 years after treatment
Correlation between the two PCR/NGS detection methods - appreciation of the NGS method sensitivity compared to the PCR.
Until 2 years after treatment
Detailed molecular characterization of genes alterations implicated in cervical oncogenesis.
Time Frame: Until 2 years after treatment
The characterization of HPV types and HPV integration sites as well as the sequencing of representative panel of genes involved in the tumorigenesis pattway.
Until 2 years after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Curie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 29, 2014

Primary Completion (Actual)

September 27, 2018

Study Completion (Actual)

September 27, 2018

Study Registration Dates

First Submitted

July 1, 2015

First Submitted That Met QC Criteria

September 17, 2015

First Posted (Estimated)

September 18, 2015

Study Record Updates

Last Update Posted (Estimated)

September 8, 2025

Last Update Submitted That Met QC Criteria

September 2, 2025

Last Verified

March 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IC 2013-06

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe